Which patients are suitable for cimepilimab? What issues need attention?

Cemiplimab (cemiplimab-rwlc), as a programmed death receptor-1 (PD-1) blocking antibody, has shown significant efficacy in the field of cancer treatment in recent years. However, not all cancer patients are suitable for this drug. This article will provide a detailed analysis of which patients are suitable for the use of cimepilimab and what issues need to be paid attention to during use.

First of all, cimepilimab is mainly suitable for the following types of patients: patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not suitable for curative surgery or radiotherapy; patients with locally advanced basal cell carcinoma (laBCC) or metastatic basal cell carcinoma (mBCC) , patients who have been previously treated with a hedgehog pathway inhibitor or who are ineligible for this treatment; and adult patients with locally advanced or metastatic non-small cell lung cancer who do not have EGFR, ALK, or ROS1 abnormalities, or who are in combination with platinum-based chemotherapy, or whose tumors have high PD-L1 expression and are suitable for treatment as a single agent.

For patients who are candidates for cimepilimab, here are some issues to be aware of:

1. Before starting to use cimipilimab, be sure to inform your doctor about your medical history, especially if you have ever had immune system diseases (such as lupus, ulcerative colitis, or Crohn's disease), neurological problems (such as myasthenia gravis or Guillain-Barre syndrome), etc.

2. If the patient has ever received chest radiation therapy or an organ transplant, he or she also needs to inform the doctor, because these conditions may affect the use of cimepilimab.

3. For female patients, a negative pregnancy test may be required before starting cimipilimab to ensure that the drug will not cause harm to the fetus. Effective contraception should be used to prevent pregnancy while taking this medication and for at least4 months after the last dose.

4. Female patients should not breastfeed while taking cimipilimab and for at least 4 months after the last dose to avoid passing the drug to the baby through breast milk.

In summary, cimepilimab is an effective treatment for patients with certain cancers. However, before use, patients need to fully understand their condition and drug indications, and fully communicate with their doctors. During use, you also need to strictly abide by the doctor's medication instructions and pay attention to relevant matters to ensure the safety and effectiveness of the drug. It is reported that cimipilimab is only available and sold in overseas markets, with a box in the European market priced at approximately More than 40,000 yuan. When purchasing, be sure to choose formal channels and carefully identify the authenticity of the medicine.